Abstract: A first ball ramp half includes a first ball ramp plate grounded within a housing against translation that defines first portions of respective one or more ramped ball receiving recesses. A second ball ramp half includes a gear plate supported within the housing for rotation relative to the first ball ramp plate and grounded within the housing against translation relative to the first ball ramp plate that has gear teeth, a second ball ramp plate supported within the housing for rotation relative to the first ball ramp plate that defines complementary second portions of the respective one or more ramped ball receiving recesses, and a joint coupling the gear plate to the second ball ramp plate. The joint imparts rotation of the gear plate to the second ball ramp plate, and is permissive of translation of the second ball ramp plate relative to the first ball ramp plate.

Abstract: A modular man-lift apparatus includes a receiver unit having a trailer attachment along one end, a power winch, and an articulating connector along a distal end. A main shaft assembly is secured to the articulating connector, and a sliding unit having a plurality of opposing wheels is secured to the shaft assembly. A lift basket is secured onto the sliding unit, and a stabilizer unit extends outward from the receiver unit.

Abstract: The present invention relates to highly selective phosphodieterase (PDE) enzyme inhibitors and to their use in pharmaceutical articles of manufacture. In particular, the present invention relates to potent inhibitors of cyclic guanosine 3?,5?-monophosphate specific phosphodiesterase type 5 (PDE5) that when incorporated into a pharmaceutical product at about 1 to about 20 mg unit dosage are useful for the treatment of sexual dysfunction.

Abstract: The present invention relates to highly selective phosphodiesterase (PDE) enzyme inhibitors and to their use in pharmaceutical articles of manufacture. In particular, the present invention relates to potent inhibitors of cyclic guanosine 3′,5′-monophosphate specific phosphodiesterase type 5 (PDES) that when incorporated into a pharmaceutical product at about 1 to about 20 mg unit dosage are useful for the treatment of sexual dysfunction.